| Bioactivity | Nilotinib-d6 is a deuterium labeled Nilotinib. Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity[1]. | |||||||||
| Name | Nilotinib-d6 | |||||||||
| CAS | 1268356-17-7 | |||||||||
| Formula | C28H16D6F3N7O | |||||||||
| Molar Mass | 535.55 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Weisberg E, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood. 2007 Mar 1;109(5):2112-20. |
Nilotinib-d6
CAS: 1268356-17-7 F: C28H16D6F3N7O W: 535.55
Nilotinib-d6 is a deuterium labeled Nilotinib. Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with a
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.